Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1995-08-31
1998-04-21
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
A61K 9127
Patent
active
057415145
ABSTRACT:
A method of reducing the serum Lp(a) concentration in a subject is disclosed. A suspension of small, unilamellar vesicles composed primarily of phospholipids, similar in nature to those of egg phosphatidylcholine, is administered parenterally to a subject having or at risk for developing a disease condition associated with an elevated serum Lp(a) concentration. In the method, liposomes are infused over an extended period of time of at least several weeks, until a significant drop in serum Lp(a) concentration is observed.
REFERENCES:
patent: 4812314 (1989-03-01), Barenholz et al.
patent: 5489611 (1996-02-01), Lee
"Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein"--1986 Elsev Science Publishers B.V. (Biomedical Division); Williams et al.
"Serum Lipoprotein (a) Levels Before and After Subtotal Thyroidectomy in Subjects With Hyperthyroidism"--Metabolism, vol. 44, No. 1 (Jan.), 1995: pp. 4-7; Yamamoto et al.
"The Relationship Between Serum Lipoprotein(a) and Restenosis After Initial Elective Percutaneous Transluminal Coronary Angioplasty"--Japanese Circulation Journal--vol. 57, Aug. 1993; Tenda et al.
"Perspectives in Biology and Medicine"--Perspectives in Biology and Medicine, 27, 3--Spring 1984; Williams et al.
"Low Levels of Serum Apolipoprotein A I and A II in Senile Dementia"--The Japanese Journal of Psychiatry and Neurology, vol. 48 No. 3, 1994; Kuriyama et al.
"Increased Concentrations of Serum Lp(a) Lipoprotein in Patients With Primary Gout"--Annals of the Rheumatic Diseases 1995; 54: 90-93; Takahashi et al.
"Elevated Serum Lp(a) Levels in the Early and Advanced Stages of Breast Cancer"--Cancer Biochem, Biophys., 1994, vol. 14, pp. 133-136; Kokoglu et al.
"Lipoprotein(a) in Type 1 Diabetic Patients with Renal Disease"--Original Articles--May 11, 1994; Groop et al.
"Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty by Reducing Lipoprotein (a) Levels with Low-Density Lipoprotein Apheresis"--Jun. 1, 1994, vol. 73, No. 15; Daida et al.
Elevated Serum Lipoprotein(a) is a Risk Factor for Clinical Recurrence After Coronary Balloon Angioplasty--Circulation vol. 91, No. 5, Mar. 1, 1995; Desmarais et al.; Desmarais et al.
Barenholz Yechezkel
Chajek Tova
Shmeeda Hilary
Kishore Gollamudi S.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Method for reducing serum lipoprotein(a) concentration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing serum lipoprotein(a) concentration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing serum lipoprotein(a) concentration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2055403